Literature DB >> 28836366

Lipoteichoic acid upregulates plasminogen activator inhibitor-1 expression in parapneumonic effusions.

Kai-Ling Lee1, Wei-Lin Chen2, Ray-Jade Chen3,4, Kevin S Lai1, Chi-Li Chung1,5.   

Abstract

BACKGROUND AND
OBJECTIVE: Parapneumonic effusion (PPE) is commonly caused by Gram-positive bacteria (GPB) and often presents with pleural loculation, which is characterized by overproduction of plasminogen activator inhibitor (PAI)-1. Lipoteichoic acid (LTA), a surface adhesion molecule of GPB, binds to the pleural mesothelium and triggers inflammation. However, the effects of LTA on PAI-1 expression in PPE and underlying mechanisms remain unclear.
METHODS: Thirty consecutive patients with PPE were enrolled, including uncomplicated culture negative (CN, n = 11), Gram-negative bacteria (GNB, n = 7) and GPB (n = 12) groups stratified by pleural fluid characteristics and bacteriology, and the effusion PAI-1 levels were measured. In addition, human pleural mesothelial cells (PMC) were treated with LTA and the expression of PAI-1 and activation of signalling pathways were assayed.
RESULTS: The median levels of PAI-1 were significantly higher in GPB (160.5 ng/mL) and GNB (117.0 ng/mL) groups than in the uncomplicated CN (58.0 ng/mL) group. In human PMC, LTA markedly upregulated PAI-1 mRNA and protein expression and enhanced elaboration of Toll-like receptor 2 (TLR2). Furthermore, LTA increased c-Jun N-terminal kinase (JNK) phosphorylation, induced activating transcription factor 2 (ATF2)/c-Jun nuclear translocation and activated PAI-1 promoter activity. Pretreatment with TLR2 siRNA significantly inhibited LTA-induced JNK phosphorylation and PAI-1 protein expression.
CONCLUSION: Culture-positive PPE, especially that caused by GPB, has a significantly higher level of PAI-1 than uncomplicated CN PPE. LTA upregulates PAI-1 expression through activation of TLR2/JNK/activator protein 1 (AP-1) pathway in human PMC. Better understanding of the modulation of PAI-1 synthesis by LTA in PPE may provide potential therapies for infected pleural effusions.
© 2017 Asian Pacific Society of Respirology.

Entities:  

Keywords:  Toll-like receptor; lipoteichoic acid; parapneumonic effusion; plasminogen activator inhibitor; pleural mesothelial cell

Mesh:

Substances:

Year:  2017        PMID: 28836366     DOI: 10.1111/resp.13148

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  4 in total

1.  Differential Pneumococcal Growth Features in Severe Invasive Disease Manifestations.

Authors:  Marien I de Jonge; Amelieke J H Cremers; Daan W Arends; Wynand Alkema; Indri Hapsari Putri; Christa E van der Gaast-de Jongh; Marc Eleveld; Jeroen D Langereis; Quirijn de Mast; Jacques F Meis
Journal:  Microbiol Spectr       Date:  2022-06-09

2.  PAI-1 Level Differences in Malignant Plural Effusion, Parapneumonic Pleuritis, and Cardiac Hydrothorax.

Authors:  Dace Zentina; Inga Stukena; Alvils Krams; Aivars Lejnieks
Journal:  Medicina (Kaunas)       Date:  2019-09-04       Impact factor: 2.430

Review 3.  Management of Pleural Infection.

Authors:  Anand Sundaralingam; Radhika Banka; Najib M Rahman
Journal:  Pulm Ther       Date:  2020-12-09

4.  HDAC Inhibitor Abrogates LTA-Induced PAI-1 Expression in Pleural Mesothelial Cells and Attenuates Experimental Pleural Fibrosis.

Authors:  Wei-Lin Chen; Mei-Chuan Chen; Shang-Fu Hsu; Shih-Hsin Hsiao; Chi-Li Chung
Journal:  Pharmaceuticals (Basel)       Date:  2021-06-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.